BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30760495)

  • 1. Early detection of pre-malignant lesions in a KRAS
    Rakhit CP; Trigg RM; Le Quesne J; Kelly M; Shaw JA; Pritchard C; Martins LM
    Dis Model Mech; 2019 Feb; 12(2):. PubMed ID: 30760495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
    Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
    Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model.
    Moghaddam SJ; Li H; Cho SN; Dishop MK; Wistuba II; Ji L; Kurie JM; Dickey BF; Demayo FJ
    Am J Respir Cell Mol Biol; 2009 Apr; 40(4):443-53. PubMed ID: 18927348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment.
    Kitagawa Y; Okumura K; Watanabe T; Tsukamoto K; Kitano S; Nankinzan R; Suzuki T; Hara T; Soda H; Denda T; Yamaguchi T; Nagase H
    Sci Rep; 2019 Aug; 9(1):11346. PubMed ID: 31383871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
    Evrard C; Ingrand P; Rochelle T; Martel M; Tachon G; Flores N; Randrian V; Ferru A; Haineaux PA; Goujon JM; Karayan-Tapon L; Tougeron D
    Dig Liver Dis; 2023 Nov; 55(11):1562-1572. PubMed ID: 37308396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
    Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR.
    Chen S; Wang Y; Wang K; Zhang L; Zhang X
    Pharmazie; 2021 Dec; 76(12):606-610. PubMed ID: 34986957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent.
    Badea CT; Athreya KK; Espinosa G; Clark D; Ghafoori AP; Li Y; Kirsch DG; Johnson GA; Annapragada A; Ghaghada KB
    PLoS One; 2012; 7(4):e34496. PubMed ID: 22485175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.
    Sutherland KD; Song JY; Kwon MC; Proost N; Zevenhoven J; Berns A
    Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4952-7. PubMed ID: 24586047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).
    Sherwood JL; Corcoran C; Brown H; Sharpe AD; Musilova M; Kohlmann A
    PLoS One; 2016; 11(2):e0150197. PubMed ID: 26918901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
    Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS
    Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
    Bádon ES; Mokánszki A; Mónus A; András C; Méhes G
    Mol Cell Probes; 2023 Feb; 67():101891. PubMed ID: 36586518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.
    Guo S; Shi X; Shen J; Gao S; Wang H; Shen S; Pan Y; Li B; Xu X; Shao Z; Jin G
    Br J Cancer; 2020 Mar; 122(6):857-867. PubMed ID: 31969677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Coverage Whole Genome Sequencing Using Laser Capture Microscopy with Combined Digital Droplet PCR: An Effective Tool to Study Copy Number and Kras Mutations in Early Lung Adenocarcinoma Development.
    Mickler EA; Zhou H; Phang TL; Geraci MW; Stearman RS; Sears CR
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
    Simmons BH; Lee JH; Lalwani K; Giddabasappa A; Snider BA; Wong A; Lappin PB; Eswaraka J; Kan JL; Christensen JG; Shojaei F
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):213-20. PubMed ID: 22684718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
    Paweletz CP; Heavey GA; Kuang Y; Durlacher E; Kheoh T; Chao RC; Spira AI; Leventakos K; Johnson ML; Ou SI; Riely GJ; Anderes K; Yang W; Christensen JG; Jänne PA
    Clin Cancer Res; 2023 Aug; 29(16):3074-3080. PubMed ID: 37279096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.